Media Release

Basel, 14 October 2010

Roche Group posts solid sales growth in first nine months

Further market share gains for Roche Diagnostics; Group confirms full-year outlook

  • Group sales increase 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs in first nine months of 2010. Excluding Tamiflu, Group sales rise 6%1 (3% in Swiss francs, 7% in US dollars).
  • Sales of cancer medicines continue to grow strongly, rising 8%.
  • Operational Excellence initiative’s Group-wide review of structures and processes well under way, with measures to be announced before year-end. Aim is to accelerate productivity improvements and strengthen innovation capacity.
  • Roche named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for second year running.
  • Roche confirms full-year outlook.
Nine months ended 30 September

Sales in millions of CHF
% change


20102009In CHF In LC*In USD
Pharmaceuticals Division28,39529,034-212
Excluding Tamiflu27,58727,030256
United States10,87811,157-311
Western Europe7,2958,026-9-3-6
Japan3,1373,490-10-12-7
International**7,0856,361111116
Diagnostics Division7,7327,365589
Roche Group36,12736,399-123
Excluding Tamiflu35,31934,395367

* LC= local currencies
**International: Asia–Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Canada, Others

See appendix to this media release for details of quarterly sales growth

Pharmaceuticals Division posts mid-single-digit growth, excluding Tamiflu

  • Sales up 1% (-2% in Swiss francs, 2% in US dollars). Excluding the expected significant decline in Tamiflu sales, divisional sales rise 5% (2% in Swiss francs), in line with Roche’s full-year outlook.
  • Growth driven mainly by Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda. Together, these medicines contribute over 1.2 billion Swiss francs in additional sales.
  • Strong growth continues in International region (+11%), driven by E7 key emerging markets.2

Diagnostics Division — above-market growth and major new products

  • Divisional sales grow 8% (5% in Swiss francs, 9% in US dollars), again ahead of the global market, driven mainly by Professional Diagnostics and Diabetes Care.
  • Major new tests for virology and oncology launched.
  • cobas 8000 modular analyser series expanded: immunoassay module launched in CE Mark countries; rollout of clinical chemistry modules in US.
  • BioImagene Inc. acquired to strengthen offering in digital pathology.

Commenting on the Group’s 2010 performance to date, Roche CEO Severin Schwan said: ‘The Roche Group recorded solid nine-month sales growth in a challenging market. I am also pleased that several of our pharma development projects reported positive data in the third quarter, notably MetMAb in lung cancer and

T-DM1 in HER2-positive breast cancer. Based on our performance to date, we expect to achieve our targets for 2010. Our Group-wide review of structures and processes as part of the Operational Excellence initiative is on track.’

Barring unforeseen events.
1) Unless otherwise stated, growth rates are in local currencies
2) Brazil, China, India, Mexico, Russia, South Korea, Turkey

Roche Group

Solid growth in first nine months

In the first nine months of 2010 Group sales rose 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs. Excluding Tamiflu sales, which as expected were significantly lower than in the previous year, Group sales increased 6% (3% in Swiss francs, 7% in US dollars). The Pharmaceuticals Division’s nine-month sales totalled 28.4 billion Swiss francs, an increase of 1% in local currencies (-2% in Swiss francs; 2% in US dollars). Excluding Tamiflu, pharmaceutical sales advanced 5% — in line with global market growth. The Diagnostics Division’s sales continued to grow faster than the global in vitro diagnostics market, advancing 8% in local currencies (5% in Swiss francs; 9% in US dollars) to 7.7 billion Swiss francs.

Roche again recognised as global healthcare leader in Dow Jones Sustainability Index

In September Roche was named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for the second year running. This top ranking among the world’s leading sustainability-driven healthcare companies is a reflection of Roche’s commitment to its employees, communities and the environment, and positions Roche as a global leader in sustainable business practices. Roche has been included in the DJSI World and DJSI STOXX since 2004 and was first named Supersector Leader in Healthcare in 2009.

Full-year outlook confirmed

Despite lower Tamiflu sales (expected to total up to 1 billion Swiss francs in the current year, down from 3.2 billion Swiss francs in 2009) and the more challenging market environment, Roche confirms its full-year outlook for 2010 on the basis of the positive nine-month sales performance. Barring unforeseen events, Roche expects local-currency sales growth in the mid-single-digit range for the Group and the Pharmaceuticals Division in 2010 (excluding Tamiflu sales). Full-year sales by the Diagnostics Division are expected to grow significantly ahead of the market. Roche is also aiming for double-digit growth in core earnings per share at constant exchange rates.

Read the entire media release

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Disclaimer: Cautionary statement regarding forward-looking statements
This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.